Video

New superbug reaches the U.S.

CDC officials are working with health authorities to identify how the patient may have contracted the bacteria, including reviewing recent hospitalizations and other healthcare exposures


Researchers have found a person in the United States carrying bacteria resistant to antibiotics of last resort, according to an article on The Washington Post website.

Researchers worry that its colistin-resistance gene, known as mcr-1, could spread to other bacteria that can already evade other antibiotics.

Colistin is the antibiotic of last resort for particularly dangerous types of superbugs, including CRE, which health officials call a “nightmare bacteria.” 

CDC officials are working with health authorities to identify how the patient may have contracted the bacteria, including reviewing recent hospitalizations and other healthcare exposures.

Read the article.

 



June 7, 2016


Topic Area: Industry News


Recent Posts

Griffin Health Improves Patient Safety and Prevents HAIs with Electronic Hand Hygiene System

Case study: The system is used in all patient units, including the emergency department and ambulatory services.


Virginia Hospital Goes into Lockdown Following Admission of Shooting Victim

The hospital followed standard protocol by restricting access to ensure safety.


Ground Broken on Adena Fayette Medical Center

The 65,000-square-foot facility is slated to open in 2027.


University of Mississippi Medical Center Acquires Merit Health Madison

Merit Health Madison will now operate under the name UMMC Madison.


Preventing Slips and Falls in Hospitals

Flooring type, matting and cleaning programs all contribute to safer facilities.


 
 


FREE Newsletter Signup Form

News & Updates | Webcast Alerts
Building Technologies | & More!

 
 
 


All fields are required. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 
 
 
 

Healthcare Facilities Today membership includes free email newsletters from our facility-industry brands.

Facebook   Twitter   LinkedIn   Posts

Copyright © 2023 TradePress. All rights reserved.